Aadibio provides a cloud‑native platform that centralizes bio‑informatics pipelines, data storage, and collaborative workspaces for life‑science and biotech organizations. The platform automates routine analyses, offers version‑controlled datasets, and integrates with LIMS and major cloud services, enabling scalable, reproducible workflows and interactive visualizations for genomics, proteomics, and cell‑based assays.

AnaCardio is developing novel inotropic agents that enhance cardiomyocyte contractility through the ghrelin signaling pathway, aiming to improve cardiac output without increasing oxygen consumption or mortality. This approach addresses the unmet need for effective treatments that target impaired contractility in heart failure patients, potentially improving organ function and quality of life.

Epsilogen develops immunoglobulin E (IgE) antibodies, specifically targeting solid tumors like ovarian cancer, to enhance treatment efficacy through improved tumor access and potency. Their lead candidate, MOv18 IgE, is the first therapeutic IgE antibody in clinical trials, demonstrating safety and early signs of clinical activity in patients with folate receptor alpha positive cancers.

Gain Therapeutics is developing pharmacological chaperones using AI-supported 3D structural biology and proprietary physics-based models to target allosteric binding sites on proteins implicated in rare metabolic disorders. Their lead drug candidate, GT-02287, aims to treat GBA-Parkinson’s disease and other neurodegenerative conditions by modulating protein function to restore cellular homeostasis.

Geneos Therapeutics develops personalized therapeutic cancer vaccines (PTCVs) using its proprietary GT-EPIC™ platform, which customizes DNA plasmids to encode up to 40 unique neoantigens from a patient's tumor. This approach aims to enhance the immune response against cancer by generating tumor-infiltrating lymphocytes that target and potentially eradicate cancer cells throughout the body.

GreenBone Ortho develops wood-derived bone implants using a proprietary multi-step process that transforms rattan wood into a biocompatible biomaterial for bone regeneration. These implants provide structural support for various clinical applications, including bone fractures, non-unions, and bone loss, facilitating effective healing and restoration of bone integrity.

iOnctura develops precision oral small molecules targeting neglected and hard-to-treat cancers by modulating key signaling pathways, including allosteric modulation of PI3Kδ and inhibition of autotaxin. Their therapies aim to reduce the severe side effects associated with conventional treatments, thereby improving patient healthspan and overall survival.

Kither Biotech develops signal transduction modulators, specifically the cAMP modulating peptide KIT2014 and the PI3K inhibitor KITCL27, for the treatment of rare respiratory diseases such as cystic fibrosis and idiopathic pulmonary fibrosis. These therapies target critical pathways involved in lung function, addressing the persistent lung infections and breathing difficulties associated with these conditions.

NeoPhore develops first‑in‑class small‑molecule inhibitors that transiently block DNA mismatch repair (MMR) in tumor cells, chemically mimicking the MMR‑deficient phenotype that responds to checkpoint inhibitor immunotherapy. By inducing a reversible MMR‑deficient state, their therapy reprograms otherwise resistant MMR‑proficient cancers to become immunogenic, enabling combination with existing chemotherapy, targeted therapy, or immunotherapy regimens and expanding the pool of patients who can benefit from durable immune responses.

Personal Genome Diagnostics provides kitted, end‑to‑end comprehensive genomic profiling solutions for solid tumor tissue and liquid biopsy samples that can be run in‑house. Their FDA‑cleared and CE‑IVD marked elio kits cover 500+ cancer‑related genes and include an automated bioinformatics pipeline that delivers clinical‑grade reports in as few as five days, enabling laboratories to obtain rapid, reliable genomic insights and support personalized cancer treatment decisions.

Roca Therapeutics develops first-in-class small molecules targeting uveal melanoma and its associated neovascular complications, utilizing a platform focused on mechanisms of angiogenesis and chronic immunosuppressive inflammation. The company aims to provide effective treatment options for patients suffering from rare cancers and related ocular disorders, improving their quality of life and treatment outcomes.

Sibylla Biotech develops small molecule folding interfering degraders (FIDs) using its proprietary Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) platform, which employs computer simulations and AI to induce the degradation of target proteins. This approach targets proteins involved in various diseases, addressing the need for new therapeutics in multiple therapeutic areas.

This company develops mecillinam and pivmecillinam, antibiotics used to treat complicated and uncomplicated urinary tract infections. Their therapies target multi-drug resistant bacterial infections, providing clinicians with effective treatment options.